Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: PROLIXIN DECANOATE
Published 2025-12-23 · Last reviewed 2025-12-30 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Fluphenazine decanoate is a long-acting injectable formulation used for schizophrenia maintenance when depot dosing supports adherence.
It is a high-potency first-generation antipsychotic (FGA) with strong dopamine D2 antagonism. Compared with many SGAs it tends to have lower metabolic burden but higher risk of EPS and tardive dyskinesia.
Depot dosing is typically every 2–4 weeks. Because drug release is prolonged, clinical changes after dose adjustments can lag, so response assessment often spans multiple injection cycles.
For depot interval comparisons and practical workflow, see the LAI Navigator and the compare tool.
Fluphenazine decanoate is generally used when an FGA is effective and the team prefers a depot schedule to reduce missed-dose relapse. Major constraints are movement-disorder risk (including tardive dyskinesia), QTc considerations, and slower dose "steerability" versus oral therapy.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Fluphenazine is a potent dopamine D2 receptor antagonist with antipsychotic effects mediated primarily through dopamine blockade.
High D2 occupancy contributes to clinical efficacy but also to higher EPS and prolactin-related adverse effects relative to many SGAs.